Compare Arko Corp. (ARKO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Arko Corp. vs Regeneron Pharmaceuticals Inc — how do they compare? Arko Corp. trades at $8.07 (market cap $905.34M), while Regeneron Pharmaceuticals Inc trades at $664.52 (market cap $69.67B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 77× Arko Corp.'s market cap, and Arko Corp. pays the higher dividend (1.49%). Which is the better fit depends on your goals.
| ARKO | REGN | |
|---|---|---|
Market Cap | $905.34M | $69.67B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.64 | $812.27 |
52-Week Low | $3.82 | $542.52 |
Enterprise Value | $3.08B | $63.62B |
Dividend Yield | 1.49% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO trades at $8.07, up 1.25% today, with a bullish technical signal from moving averages. The company reported Q1 2026 earnings that beat expectations, though revenue has declined from $9.4B in 2023 to $7.6B in 2025. Valuation metrics show a high P/E of 40.35 but a low P/S of 0.12, and the firm maintains positive operating cash flow of $193M in 2025. A recent dividend of $0.03 per share was declared for May 2026.
ARKO presents a mixed outlook; low valuation multiples and defensive positioning amid inflation offer value, but declining revenue and thin net margins near 0.38% pose profitability risks. Analyst consensus is entirely Hold, reflecting caution. Key risks include competitive pressures in fuel distribution and sensitivity to economic cycles, requiring careful monitoring of cash flow sustainability for dividend coverage.
Regeneron (REGN) trades at $664.52, down 0.54% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong fundamentals with a P/E of 16.22, net income margin of 29.65%, and consistent earnings beats. Recent FDA acceptance for cemdisiran review and inclusion in a manufacturing facility pilot program highlight positive developments. Cash flow improved in 2025 with net cash flow of $634.70 million.
Outlook remains positive with a consensus price target of $764.50, implying 15% upside, supported by 69% analyst buy ratings. Risks include regulatory hurdles, competitive pressures, and dependence on key drug performance. The stock presents a compelling opportunity for growth investors given its valuation and pipeline progress, though near-term volatility may persist around earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
